Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial

The phase 3 COMPASSION-16 trial demonstrates significant progression-free survival (PFS) and overall survival (OS) benefits with cadonilimab plus standard therapy in patients with persistent, recurrent, or metastatic cervical cancer. This analysis aims to assess efficacy outcomes in patient subgroups of COMPASSION-16. The dual primary endpoints of COMPASSION-16 are PFS, assessed by the blinded independent central review (BICR) according to RECIST version 1.1, and OS. The secondary endpoint is objective response rate. In this subgroup analysis, the PFS, OS and objective response rate are evaluated in subgroups including bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score (CPS), metastatic disease at baseline, platinum use, and age. With median follow-up of 25.6 months, hazard ratios (HRs) for PFS favour cadonilimab group in all subgroups. Moreover, the addition of cadonilimab is also associated with prolonged overall survival. This subgroup analysis confirms that improvements in progression-free and overall survival are consistent with the primary results of the COMPASSION-16 study across diverse patient profiles.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-03-14
DOI
https://doi.org/10.1038/s41467-026-69965-1
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial

Baiyong Li, T. Wang, H. Lou, Hongyi Cai et al.
Nature Communications
Endometrial and Cervical Cancer Treatments
article

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial

Baiyong Li, T. Wang, H. Lou, Hongyi Cai, Sihai Liao, Yijing Ye, Guoping Sun, Xiaojian Yan, Xianling Liu, Bairong Xia, Desheng Yao, Lijing Zhu, Pengpeng Qu, Mingxiu Hu, Weihu Wang, Yuzhi Li, Yunxia Li, Chang Liu, Xiaohua Wu, Ping Yan, Zhengzheng Chen, Zhiqing Liang, Guzhalinuer Abulizi, Ting Liu, Xiaohong Wang, Qiu Tang, Tao Wu, Bing Yang, Hongyan Guo, Genhai Zhu, Dongmei Lu, Chunyan Wang, Mei Pan, Bing Wei, Youguo Chen, Jing Wang, Ying Tang, Hong (Vivien) Zhu, Qingshan Li, Yifeng Wang, Tao Wang, Fei Wang, Ying Cheng, Hongbing Cai, Yi Huang, Qiuhong Tian, Hua Qian, Guiling Li, Xiumin Li, Yang Sun, Funan Liu, Ke Wang, Meili Sun, Zhongmin M. Wang, Dan Li, Lihong Chen, Yunyan Zhang, Michelle Xia, Hongying Yang, Lina Hu, Dapeng Li, Qiang Zhou, Kun Song, Min Hao, Hui Zhang
article en

Abstract

The phase 3 COMPASSION-16 trial demonstrates significant progression-free survival (PFS) and overall survival (OS) benefits with cadonilimab plus standard therapy in patients with persistent, recurrent, or metastatic cervical cancer. This analysis aims to assess efficacy outcomes in patient subgroups of COMPASSION-16. The dual primary endpoints of COMPASSION-16 are PFS, assessed by the blinded independent central review (BICR) according to RECIST version 1.1, and OS. The secondary endpoint is objective response rate. In this subgroup analysis, the PFS, OS and objective response rate are evaluated in subgroups including bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score (CPS), metastatic disease at baseline, platinum use, and age. With median follow-up of 25.6 months, hazard ratios (HRs) for PFS favour cadonilimab group in all subgroups. Moreover, the addition of cadonilimab is also associated with prolonged overall survival. This subgroup analysis confirms that improvements in progression-free and overall survival are consistent with the primary results of the COMPASSION-16 study across diverse patient profiles.

Nature Communications
Hebei Medical University (CN), University of Science and Technology of China (CN), Fujian Medical University (CN), Central South University (CN), Nanchang University (CN), Army Medical University (CN), Xinjiang Medical University (CN), Harbin Medical University (CN), Guangxi Medical University (CN), Bengbu Medical College (CN), Guangdong Medical College (CN), Shanxi Medical University (CN), Zunyi Medical University (CN), Dalian Medical University (CN), Chengde Medical University (CN), Anhui Medical University (CN), Nantong University (CN), Peking University (CN), Kunming Medical University (CN), Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Wuhan University (CN), Soochow University (CN), Affiliated Hospital of Southwest Medical University (CN), Fudan University Shanghai Cancer Center (CN), Peking University Cancer Hospital (CN), Suizhou Central Hospital (CN), Second Affiliated Hospital of Chongqing Medical University (CN), Linyi People's Hospital (CN), Jilin Province Tumor Hospital (CN), Zhejiang Cancer Hospital (CN), Shandong Tumor Hospital (CN), Tumor Hospital of Xinjiang Medical University (CN), Third Affiliated Hospital of Harbin Medical University (CN), Fourth Hospital of Hebei Medical University (CN), Jinan Central Hospital (CN), Zhongshan People's Hospital (CN), Jiangxi Maternal and Child Health Hospital (CN), Hebei General Hospital (CN), Nanjing Drum Tower Hospital (CN), Gansu Provincial Hospital (CN), Hunan Cancer Hospital (CN), Shandong Provincial Hospital (CN), Zhongnan Hospital of Wuhan University (CN), Zhujiang Hospital (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN), The First People's Hospital of Changde (CN), Tianjin Central Hospital of Gynecology Obstetrics (CN), Ningxia Medical University (CN), Hainan General Hospital (CN), Wuhan Union Hospital (CN), Anhui Provincial Hospital (CN), Southwest Hospital (CN), Second Hospital of Shanxi Medical University (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), First Affiliated Hospital of Anhui Medical University (CN), Women's Hospital, School of Medicine, Zhejiang University (CN), Ningxia Medical University General Hospital (CN), First Hospital of China Medical University (CN), Peking University Third Hospital (CN), Second Affiliated Hospital of Jilin University (CN), Fujian Provincial Cancer Hospital (CN), Second Affiliated Hospital of Anhui Medical University (CN), First Affiliated Hospital of Bengbu Medical College (CN), First Affiliated Hospital of Soochow University (CN), Second Xiangya Hospital of Central South University (CN), Chongqing Cancer Hospital (CN), Tumor Hospital of Guangxi Medical University (CN), Affiliated Hospital of Guangdong Medical College Hospital (CN), Xiangya Hospital Central South University (CN), Tongji Hospital (CN), Shanxi Provincial People’s Hospital (CN), Hubei Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Qilu Hospital of Shandong University (CN), Shandong First Medical University (CN), First Hospital of Lanzhou University (CN), Union Hospital (CN), First Affiliated Hospital of Nanchang University (CN), Affiliated Hospital of Zunyi Medical College (CN), Lanzhou University (CN), Chongqing Medical University (CN), China Medical University (CN)
Good health and well-being
Openalex Percentile: Top 21%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.